Accelerate Your mAb Development: From Bench to Commercial Scale
Credit: iStock.
Monoclonal antibody (mAb) therapeutics are rapidly advancing, but so are the pressures on the teams developing them. Process bottlenecks, legacy purification technologies, and screening strategies that don't translate to scale are costing programs time, yield, and money.
This compendium brings together five expert resources covering the full development arc—from CDMO-compatible process design and resin selection to next-generation purification strategies for complex modalities like bispecifics and ADCs.
Download this compendium to discover:
- How to design scalable mAb processes that survive tech transfer to a CDMO without costly rework
- Why traditional polishing workflows fall short for bispecific antibodies and ADCs—and what to use instead
- Key resin selection criteria that balance purity, yield, and cost at manufacturing scale
Sponsored by
Download the Compendium for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
